138 related articles for article (PubMed ID: 27022050)
1. Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT".
Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White J; Tershakovec AM; Blazing MA; Braunwald E
Circulation; 2016 Mar; 133(13):e463. PubMed ID: 27022050
[No Abstract] [Full Text] [Related]
2. Letter by Robinson Regarding Articles, "Bringing Back Targets to 'IMPROVE' Atherosclerotic Cardiovascular Disease Outcomes: The Duel for Dual Goals; Are Two Targets Better Than One?" and "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT".
Robinson JG
Circulation; 2016 Mar; 133(13):e461. PubMed ID: 27022048
[No Abstract] [Full Text] [Related]
3. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E
Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412
[TBL] [Abstract][Full Text] [Related]
4. Response to the Letter Regarding Article, "Bringing Back Targets to 'IMPROVE' Atherosclerotic Cardiovascular Disease Outcomes: The Duel for Dual Goals; Are Two Targets Better Than One?".
Michos ED; Martin SS; Blumenthal RS
Circulation; 2016 Mar; 133(13):e462. PubMed ID: 27022049
[No Abstract] [Full Text] [Related]
5. Bringing back targets to "IMPROVE" atherosclerotic cardiovascular disease outcomes: the duel for dual goals; are two targets better than one?
Michos ED; Martin SS; Blumenthal RS
Circulation; 2015 Sep; 132(13):1218-20. PubMed ID: 26330413
[No Abstract] [Full Text] [Related]
6. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
[TBL] [Abstract][Full Text] [Related]
7. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes.
Li L; Zhang M; Su F; Li Y; Shen Y; Shen J; Zhang D
Lipids Health Dis; 2015 Feb; 14():10. PubMed ID: 25879728
[TBL] [Abstract][Full Text] [Related]
9. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
Lancellotti P; Pierard LA; Scheen AJ
Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
[TBL] [Abstract][Full Text] [Related]
10. Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria.
Virani SS; Akeroyd JM; Nambi V; Maddox TM; Gillette MA; Michael Ho P; Rumsfeld J; Petersen LA; Ballantyne CM
Am J Med; 2015 Nov; 128(11):1253-6. PubMed ID: 26071828
[TBL] [Abstract][Full Text] [Related]
11. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
Yoon HS; Kim SH; Kim JK; Ko SH; Ko JE; Park SJ; Park MG; Lee JH; Hyon MS
Ann Pharmacother; 2011 Jul; 45(7-8):841-9. PubMed ID: 21693699
[TBL] [Abstract][Full Text] [Related]
12. Ezetimibe plus a Statin after Acute Coronary Syndromes.
Singh JS; Struthers AD; Lang CC
N Engl J Med; 2015 Oct; 373(15):1476. PubMed ID: 26444741
[No Abstract] [Full Text] [Related]
13. Ezetimibe plus a Statin after Acute Coronary Syndromes.
Richard T; Lelubre C; Vanhaeverbeek M
N Engl J Med; 2015 Oct; 373(15):1475-6. PubMed ID: 26444740
[No Abstract] [Full Text] [Related]
14. Ezetimibe plus a Statin after Acute Coronary Syndromes.
Nunes JP
N Engl J Med; 2015 Oct; 373(15):1475. PubMed ID: 26444739
[No Abstract] [Full Text] [Related]
15. Ezetimibe plus a Statin after Acute Coronary Syndromes.
Patti G; Cavallari I
N Engl J Med; 2015 Oct; 373(15):1474-5. PubMed ID: 26444738
[No Abstract] [Full Text] [Related]
16. Ezetimibe plus a Statin after Acute Coronary Syndromes.
Egom EE
N Engl J Med; 2015 Oct; 373(15):1474. PubMed ID: 26444737
[No Abstract] [Full Text] [Related]
17. Ezetimibe plus a Statin after Acute Coronary Syndromes.
Couture P; Durand M; Laskine M
N Engl J Med; 2015 Oct; 373(15):1473-4. PubMed ID: 26444736
[No Abstract] [Full Text] [Related]
18. Ezetimibe plus a Statin after Acute Coronary Syndromes.
Silbernagel G; Baumgartner I; März W
N Engl J Med; 2015 Oct; 373(15):1473. PubMed ID: 26444735
[No Abstract] [Full Text] [Related]
19. Ezetimibe plus a Statin after Acute Coronary Syndromes.
Cannon CP; Blazing MA; Braunwald E
N Engl J Med; 2015 Oct; 373(15):1476-7. PubMed ID: 26444734
[No Abstract] [Full Text] [Related]
20. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.
Blazing MA; Giugliano RP; Cannon CP; Musliner TA; Tershakovec AM; White JA; Reist C; McCagg A; Braunwald E; Califf RM
Am Heart J; 2014 Aug; 168(2):205-12.e1. PubMed ID: 25066560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]